Programme 2020

Friday: September 11, 2020

10:00 (EST)

Introduction & Virtual Meeting Objectives
John Gribben

10:05-10:55

Session I: Hodgkin’s Lymphoma

Chair: Peter Johnson & Pier Luigi Zinzani 

  • Early-stage unfavorable cHL; Peter Borchmann
  • KEYNOTE 204; Pier Luigi Zinzani
  • Hodgkin’s Lymphoma in the era of targeted therapy; Peter Johnson / Amin Islam 


Roundtable Discussion

10:55-11:45

Session II: Immunotherapy/Microenvironment

Chair: David Maloney & Stephen Ansell

  • Crosstalk between lymphocytes and their microenvironment; Patricia Pérez Galán
  • PRAME expression and the tumour microenvironment; David Scott
  • CBT in specific lymphoma subtypes; Stephen Ansell


Roundtable Discussion

11:45-12:35

Session III: Novel Therapies Part I

Chairs: Laurie Sehn & Franck Morschhauser

  • Novel ADCs; Laurie Sehn
  • CD20 / CD3 bispecific antibodies: How to choose?; Franck Morschhauser
  • Oral PI3K delta (δ) inhibitors in lymphoma;


Roundtable Discussion

12:35-15:00

Roundup of Day 1:
John Gribben, Stephen Ansell, Laurie Sehn & Franck Morschhauser

Saturday: September 12, 2020

10:00-10:55

Session IV: Novel Therapies Part II

  • Novel BTK inhibitors: how to choose?; Tom Witzig
  • SINE inhibitors: Selinexor; Sundar Jagannath
  • Tafasitamab (MOR208) in DLBCL; Gilles Salles


Roundtable Discussion

10:55-11:45

Session V: T-cell Therapies for Lymphoma

Chairs: Cath Bollard & Jeremy Abramson 

  • CD19-CAR-T cells; Jeremy Abramson
  • CD30, CD5 and/or 7 CAR-T cells; Cath Bollard
  • T cell-engaging therapies – BiTEs and beyond; Ralf C. Bargou


Roundtable Discussion

11:45-12:00

Final Virtual Meeting Summary & Conclusions
iwNHL Scientific Committee

© 2014 - 2020 World Health Communications Ltd

Media Partner:

Meeting Organizers: